ClinicalTrials.Veeva

Menu

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Roche logo

Roche

Status and phase

Completed
Phase 2

Conditions

HIV Infections

Treatments

Drug: Zidovudine
Drug: Saquinavir
Drug: Lamivudine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002190
229N
NV15114

Details and patient eligibility

About

To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

Full description

A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

  • HIV antibody positive.
  • CD4 count >= 150 and <= 500 cells/mm3.

Exclusion Criteria

Prior Medication:

Excluded:

  • Prior antiretroviral therapy.
  • Prior protease inhibitor therapy.

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems